148 related articles for article (PubMed ID: 30732962)
1. Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.
Teft WA; Winquist E; Nichols AC; Kuruvilla S; Richter S; Parker C; Francis P; Trinnear M; Lukovic J; Bukhari N; Choi YH; Welch S; Palma DA; Yoo J; Kim RB
Oral Oncol; 2019 Feb; 89():72-78. PubMed ID: 30732962
[TBL] [Abstract][Full Text] [Related]
2. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).
Driessen CM; Ham JC; Te Loo M; van Meerten E; van Lamoen M; Hakobjan MH; Takes RP; van der Graaf WT; Kaanders JH; Coenen MJH; van Herpen CM
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30999660
[TBL] [Abstract][Full Text] [Related]
3. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.
Noronha V; Sharma V; Joshi A; Patil VM; Laskar SG; Prabhash K
Indian J Cancer; 2017; 54(2):453-457. PubMed ID: 29469077
[TBL] [Abstract][Full Text] [Related]
6. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
[TBL] [Abstract][Full Text] [Related]
7. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
Espeli V; Zucca E; Ghielmini M; Giannini O; Salatino A; Martucci F; Richetti A
Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
[TBL] [Abstract][Full Text] [Related]
8. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
9. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.
Geiger JL; Lazim AF; Walsh FJ; Foote RL; Moore EJ; Okuno SH; Olsen KD; Kasperbauer JL; Price DL; Garces YI; Ma DJ; Neben-Wittich MA; Molina JR; Garcia JJ; Price KA
Oral Oncol; 2014 Apr; 50(4):311-8. PubMed ID: 24467937
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
Planting AS; de Mulder PH; de Graeff A; Verweij J
Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
[TBL] [Abstract][Full Text] [Related]
15. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
16. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Karner K; Strojan P; Schild SE
Oral Oncol; 2016 Aug; 59():67-72. PubMed ID: 27424184
[TBL] [Abstract][Full Text] [Related]
19. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
20. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
